Navigation Links
AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Date:3/3/2008

QUEBEC CITY and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS;TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, and Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that they have entered into a definitive purchase and sale agreement with respect to all rights related to the manufacture, production, distribution, marketing, sale and/or use of miltefosine for an aggregate purchase price of Cdn$9.125 million payable in cash, subject to certain post-closing purchase price adjustments. Miltefosine, sold under the brand name Impavido(R) throughout the world, recorded revenues of Euro 2.5 million in 2007. Completion of the transactions contemplated by the purchase agreement is subject to customary closing conditions, including the parties having received certain third-party consents and approvals.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "Last fall, we put forth our new focused business strategy which included identifying non-core assets and actively seeking to divest them as a way to infuse non-dilutive funds into the Company. We are very pleased to have entered into an agreement for the sale of the compound, miltefosine, and look forward to consummating the deal in the near future."

"This transaction marks the first time that Paladin has acquired international rights to a patented, medically important product", said Jonathan Ross Goodman, President and CEO of Paladin Labs. "This transaction is expected to be immediately accretive to earnings and it fits within our broader strategy to grow Paladin's revenues beyond the Canadian border."

About miltefosine

Miltefosine
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
2. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
3. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
4. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
5. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
8. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
9. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
10. DW Healthcare Partners Announces the Sale of Tandem Labs
11. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...e and Introduces Q1 2008 Guidance, FRAZER, Pa., F...ed 2007 sales of $1.727 billion, compared to sales...,s previously issued,guidance. Basic loss per comm...ng the previously announced settlement reserve, am...adjusted income per common share for the,full year...
... Technology Leadership, INDIANAPOLIS, Feb. 12 Th...wholly owned subsidiary of The Dow Chemical,Compan...ade to investors,earlier today by Jerome Peribere,...as speaking at the Goldman Sachs Agricultural Chem...rced Dow AgroSciences,technology-based strategy of...
...Corporation (NYSE: CBM ) announced that it will r... results on Thursday, February 14, 2008 after,mark.../prnh/20000613/CAMBREXLOGO ), The Company will h...r,and full year 2007 financial results., ...s Conference Call, When: Friday, Februa...
Other Biology Technology:Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 2Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 3Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 5Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 6Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 7Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 8Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 9Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 10Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 11Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 12Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 13Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 14Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 15Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 16Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 17Dow AgroSciences' Success Presented to Wall Street 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2Grooving down the helix 2Grooving down the helix 3Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 1Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 2Benefit of glinides is not proven 49380 1Benefit of glinides is not proven 49380 2Benefit of glinides is not proven 49380 37th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 17th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 27th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 3
...e investigating exactly how chemotherapy drugs kil...s and test the effectiveness of safer new agents. ...versity of Manchester,s Faculty of Life Sciences h...ti-mitotic drugs, which are used extensively for b...f drugs, which includes the agent taxol, has been ...
...imate change, researchers at BBSRC-supported Rotha...amaging aphids the peach-potato aphid (Myzus pers...er for every 1C rise in mean temperature for Janua...hid was caught on 25 April, which is almost four w...eported in BBSRC Business, the quarterly researc...
...erated in health care, computational biology, home... massive and unstructured data sets has proven cum...known as data and visual analytics is helping sift... put together individual pieces of a picture. , T...five-year grant to lead and coordinate a new initi...
Other Biology News:How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3Aphids are sentinels of climate change 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone 1.F.1 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-P5 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: